 | |
Pharmacogenomics Reporter
GenomeWeb News Premium Content
Existing subscribers login
here.
New
to Pharmacogenomics Reporter? For a trial subscription click here.
|
|
Volume 5 - Number 49 | December 19, 2007
 |
|
| In This Week's Issue |  |
RFP, Collaboration, Product Launches: NCI, Vendors Get Busy on Antibodies
Not-for-Profit Readies to Bring Protein Chips to Medically Underserved Nations
MIT Team Develops Probe for In-Cell Protein-Protein Interaction Analysis
Recent Patents of Interest in Proteomics
Proteome Sciences, Vermillion, Applera, Applied Biosysems, Celerea, NextGen, Expression Pathology, Aushon, Proteros, Merchachem, Hybrigenics, Dualsystems
William Parrett, Jason Novi, Robert Gavin, Wilhelm Lachnit, Tim Harkness
GE Healthcare, Bio-Rad, AnaSpec
|
|
|
Features
|
Studies Show Agendia Assay Could Reduce Unnecessary Chemo for Node +/- Patients
An international consortium has shown that Agendia’s MammaPrint breast cancer prognosis test can accurately identifying which lymph node-positive breast cancer patients should not receive adjuvant chemotherapy. The company also recently published data showing how the test can reduce chemotherapy treatment in node-negative breast cancer patients, and completed a study that shows it might be useful in determining the treatment for elderly patients.
|
|
FDA Updates Carbamazepine Label to Urge Genetic Testing for Rare Skin Reactions
The FDA requested makers of a drug indicated for epilepsy, bipolar disorder, and neuropathic pain to add a black box warning recommending doctors to test patients of Asian ancestry for the HLA-B*1502 polymorphism due to the increased risk of Stevens Johnson Syndrome and toxic epidermal necrolysis. Specialty labs such as LabCorp and Quest have said they can accommodate such genetic testing.
|
Snippets
New Releases
Pairings
|
![Publishing Systems Powered by iProduction [martha]](/images-genomeweb/small_iproduction_logo.gif "Publishing Systems Powered by iProduction [ martha]"){kind=logo}